All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
This ASCO 2016 oral abstract presentation took place on Sunday June 5, 9:45am–12:45pm, during the ‘Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia’ session. This session was chaired by Pr Gilles Salles, Head of the Hematology Department in South Lyon hospitals, Lyon, France.
The presentation (abstract #7507) was given by Dr Andrew M Evens, Director of the Tufts Cancer Center, Chief of the Division of Hematology/Oncology, Director of the Lymphoma Program and Professor at Tufts University School of Medicine, Boston, MA, USA.
High Risk (HR) Follicular Lymphoma (FL) is an area on great unmet clinical need. The E2408 phase IIa, open-label, multicenter study, conducted by the ECOG-ACRIN Cancer Research Group, began in May 2013 and the primary outcome measure was Overall Response Rate (ORR). It aimed to assess if bortezomib (V) can improve the CR rate achieved by standard bendamustine-rituximab (BR) induction in untreated HR stage I/II or IIIa FL. Moreover, it was investigated if the addition of lenalidomide (len) to maintenance rituximab (MR) improves rates of remission.
HR was defined as high tumor burden by GELF and/or FLIPI 3–5. Patients were randomized to one of three different treatment arms in a 1:2:2 ratio:
A) BR x 6 followed by MR x 2 years (yrs)
B) BVR x 6 (V 1.3 mg/m2 IV/SQ days 1, 4, 8, 11) then MR x 2 yrs
C) BR x 6 then MR x 2 yrs + len 20 mg/day x 1 yr
The data presented in this abstract reports on the first primary objective of CR rate with induction therapy (Tx) with arms A + C combined for induction comparison (90% power at 1-sided α of 0.15).
|
BR |
BVR |
||
FLIPI |
N |
CR % |
N |
CR % |
0–2 |
40 |
65% |
77 |
72% |
3–5 |
28 |
53% |
35 |
76% |
In conclusion, this initial report demonstrated that adding bortezomib to front-line induction with BR is feasible in high tumor burden FL patients. The CR rate for BVR was significantly superior versus BR alone. Overall, BVR was also well tolerated (neurotoxicity was less common when bortezomib was administered subcutaneously).
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox